• Twitter
  • Jobs
ProCURE oncology
  • HOME
  • ABOUT US
  • RESEARCH GROUP
    • Molleví’s Lab
    • Antolin’s Lab
    • Alemany’s & Piulats’s lab
    • Martínez-Balibrea’s Lab
    • Aytes’s Lab
    • Belver’s Lab
    • Pujana’s Lab
    • Menendez’s Lab
    • Sureda’s & Farre’s Lab
    • Casanovas’s Lab
    • Viñals’s lab
  • INNOVATION
  • NEWS
  • CONTACT
  • Menu Menu

News

Regulation of the MDM2-p53 pathway by the ubiquitin ligase HERC2

31 de October de 2019
Mol Oncol. 2020 Jan;14(1):69-86. doi: 10.1002/1878-0261.12592.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2019-10-31 10:00:002019-10-31 10:00:00Regulation of the MDM2-p53 pathway by the ubiquitin ligase HERC2

Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy

25 de October de 2019
Oncoimmunology. 2019 Jun 25;8(10):e1633235. doi: 10.1080/2162402X.2019.1633235.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2019-10-25 10:00:002019-10-25 10:00:00Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy

Tumor Expression of Cyclin-Dependent Kinase 5 (Cdk5) Is a Prognostic Biomarker and Predicts Outcome of Oxaliplatin-Treated Metastatic Colorectal Cancer Patients

17 de October de 2019
Cancers (Basel). 2019 Oct 11;11(10):1540. doi: 10.3390/cancers11101540.ABSTRACTIn…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2019-10-17 10:00:002019-10-17 10:00:00Tumor Expression of Cyclin-Dependent Kinase 5 (Cdk5) Is a Prognostic Biomarker and Predicts Outcome of Oxaliplatin-Treated Metastatic Colorectal Cancer Patients

The oncolytic adenovirus VCN-01 promotes anti-tumor effect in primitive neuroectodermal tumor models

9 de October de 2019
Sci Rep. 2019 Oct 7;9(1):14368. doi: 10.1038/s41598-019-51014-1.ABSTRACTLast…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2019-10-09 10:00:002019-10-09 10:00:00The oncolytic adenovirus VCN-01 promotes anti-tumor effect in primitive neuroectodermal tumor models

The Genetics and Mechanisms of T-Cell Acute Lymphoblastic Leukemia

2 de October de 2019
Cold Spring Harb Perspect Med. 2020 Mar 2;10(3):a035246. doi:…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2019-10-02 10:00:002019-10-02 10:00:00The Genetics and Mechanisms of T-Cell Acute Lymphoblastic Leukemia

Hyperprogression after first dose of immunotherapy in a patient with radioresistant metastasis from nonsmall cell lung cancer

1 de October de 2019
Anticancer Drugs. 2019 Nov;30(10):1067-1070. doi: 10.1097/CAD.0000000000000837.ABSTRACTImmune…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2019-10-01 10:00:002019-10-01 10:00:00Hyperprogression after first dose of immunotherapy in a patient with radioresistant metastasis from nonsmall cell lung cancer

GATA3-Controlled Nucleosome Eviction Drives MYC Enhancer Activity in T-cell Development and Leukemia

15 de September de 2019
Cancer Discov. 2019 Dec;9(12):1774-1791. doi: 10.1158/2159-8290.CD-19-0471.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2019-09-15 10:00:002019-09-15 10:00:00GATA3-Controlled Nucleosome Eviction Drives MYC Enhancer Activity in T-cell Development and Leukemia

The transcribed pseudogene RPSAP52 enhances the oncofetal HMGA2-IGF2BP2-RAS axis through LIN28B-dependent and independent let-7 inhibition

6 de September de 2019
Nat Commun. 2019 Sep 4;10(1):3979. doi: 10.1038/s41467-019-11910-6.ABSTRACTOne…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2019-09-06 10:00:002019-09-06 10:00:00The transcribed pseudogene RPSAP52 enhances the oncofetal HMGA2-IGF2BP2-RAS axis through LIN28B-dependent and independent let-7 inhibition

Virgin Olive Oil and Health: Summary of the III International Conference on Virgin Olive Oil and Health Consensus Report, JAEN (Spain) 2018

5 de September de 2019
Nutrients. 2019 Sep 1;11(9):2039. doi: 10.3390/nu11092039.ABSTRACTThe…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2019-09-05 10:00:002019-09-05 10:00:00Virgin Olive Oil and Health: Summary of the III International Conference on Virgin Olive Oil and Health Consensus Report, JAEN (Spain) 2018

m7FLIPI and targeted sequencing in high-risk follicular lymphoma

3 de September de 2019
Hematol Oncol. 2019 Dec;37(5):564-568. doi: 10.1002/hon.2674.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2019-09-03 10:00:002019-09-03 10:00:00m7FLIPI and targeted sequencing in high-risk follicular lymphoma

PI3K (Phosphatidylinositol 3-Kinase) Activation and Endothelial Cell Proliferation in Patients with Hemorrhagic Hereditary Telangiectasia Type 1

28 de August de 2019
Cells. 2019 Aug 24;8(9):971. doi: 10.3390/cells8090971.ABSTRACTHemorrhagic…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2019-08-28 10:00:002019-08-28 10:00:00PI3K (Phosphatidylinositol 3-Kinase) Activation and Endothelial Cell Proliferation in Patients with Hemorrhagic Hereditary Telangiectasia Type 1

In silico clinical trials for anti-aging therapies

25 de August de 2019
Aging (Albany NY). 2019 Aug 24;11(16):6591-6601. doi: 10.18632/aging.102180.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2019-08-25 10:00:002019-08-25 10:00:00In silico clinical trials for anti-aging therapies
Page 50 of 87«‹4849505152›»

Filter by categories

  • Alemany’s & Piulats’s lab (133)
  • Antolin's lab (36)
  • Aytes's Lab (25)
  • Belver's Lab (25)
  • Casanovas's Lab (77)
  • Martínez-Balibrea's Lab (43)
  • Menendez's Lab (121)
  • Molleví's Lab (35)
  • Pujana's Lab (110)
  • Sin categoría (5)
  • Sureda's & Farre's Lab (312)
  • Viñals's lab (111)

Twitter

Tweets by ProcureICO
Program Against Cancer Therapeutic Resistance

CONTACT US

Campus IDIBELL
(L’Hospitalet del Llobregat)
Hospital Duran i Reynals, Gran Via 199,
L’Hospitalet del Llobregat,
Barcelona 08908
Tel. +34 93 260 7952

Campus IGTP-IJC
(Badalona)
Campus Can Ruti – IGTP – Building Muntanya,
Rd. Can Ruti, Camí de les escoles s/n,
Badalona, Barcelona 08916
Tel. +34 93 554 3069

Campus IDIBGI
(Girona)
Parc Hospitalari Martí i Julià de Salt, Dr. Castany s/n,
Salt, Girona 17190
Tel. +34 872 987 087

© Copyright - Edisenius
  • Privacy Policy
  • Cookie Policy
  • Legal Notice
Scroll to top
Manage cookie consent
To offer the best experiences, we use technologies such as cookies to store and/or access device information. Consent to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Failure to consent, or withdrawal of consent, may adversely affect certain features and functions.
Functional Always active
Storage or technical access is strictly necessary for the legitimate purpose of allowing the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. Storage or technical access that is used exclusively for anonymous statistical purposes. Without a requirement, voluntary compliance by your Internet service provider, or additional records from a third party, information stored or retrieved solely for this purpose cannot be used to identify you.
Marketing
Storage or technical access is necessary to create user profiles to send advertising, or to track the user on a website or several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
See preferences
{title} {title} {title}